...
search icon
eras-img

Erasca Inc Share Price

ERAS
NSQ
$14.97
-$0.19
(-1.25%)
1D
Industry: Biotechnology Sector: Health Care

Erasca Inc Analyst Forecast

Erasca Inc Share Price Chart

Erasca Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.71B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.87M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.01 L
$16.41 H
$14.97

About Erasca Inc, Common Stock

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Erasca Inc Stock Returns

Time FrameERASSectorS&P500
1-Week Return2.67%0.28%-0.82%
1-Month Return9.74%-9.03%-6.02%
3-Month Return333.24%-6.46%-6.25%
6-Month Return610.43%7.24%-2.8%
1-Year Return867.1%0.53%13.78%
3-Year Return437.28%14.02%62.85%
5-Year Return-14%23.96%63.02%

Erasca Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Cost of Revenue829.00K2.64M3.73M3.81M3.11M[{"date":"2021-12-31","value":21.79,"profit":true},{"date":"2022-12-31","value":69.41,"profit":true},{"date":"2023-12-31","value":98.08,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":81.66,"profit":true}]
Gross Profit(829.00K)(2.64M)(3.73M)(3.81M)(3.11M)[{"date":"2021-12-31","value":-82900000,"profit":false},{"date":"2022-12-31","value":-264100000,"profit":false},{"date":"2023-12-31","value":-373200000,"profit":false},{"date":"2024-12-31","value":-380500000,"profit":false},{"date":"2025-12-31","value":-310700000,"profit":false}]
Gross Margin-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Operating Expenses124.05M244.81M137.79M179.59M128.30M[{"date":"2021-12-31","value":50.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":56.29,"profit":true},{"date":"2024-12-31","value":73.36,"profit":true},{"date":"2025-12-31","value":52.41,"profit":true}]
Operating Income(124.88M)(247.45M)(141.53M)(179.59M)(131.41M)[{"date":"2021-12-31","value":-12488300000,"profit":false},{"date":"2022-12-31","value":-24745000000,"profit":false},{"date":"2023-12-31","value":-14152500000,"profit":false},{"date":"2024-12-31","value":-17958700000,"profit":false},{"date":"2025-12-31","value":-13140500000,"profit":false}]
Total Non-Operating Income/Expense2.31M9.55M31.84M38.03M23.47M[{"date":"2021-12-31","value":6.07,"profit":true},{"date":"2022-12-31","value":25.1,"profit":true},{"date":"2023-12-31","value":83.71,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":61.7,"profit":true}]
Pre-Tax Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)[{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false},{"date":"2024-12-31","value":-16165000000,"profit":false},{"date":"2025-12-31","value":-12454600000,"profit":false}]
Income Taxes27.33M(4.64M)---[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-17,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(150.09M)(238.16M)---[{"date":"2021-12-31","value":-15009000000,"profit":false},{"date":"2022-12-31","value":-23816000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(122.76M)(242.81M)(230.59M)(161.65M)(124.55M)[{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-23059100000,"profit":false},{"date":"2024-12-31","value":-16165000000,"profit":false},{"date":"2025-12-31","value":-12454600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)[{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false},{"date":"2024-12-31","value":-16165000000,"profit":false},{"date":"2025-12-31","value":-12454600000,"profit":false}]
EPS (Diluted)(2.67)(1.96)(0.83)(0.74)(0.44)[{"date":"2021-12-31","value":-266.5,"profit":false},{"date":"2022-12-31","value":-196,"profit":false},{"date":"2023-12-31","value":-83,"profit":false},{"date":"2024-12-31","value":-74,"profit":false},{"date":"2025-12-31","value":-44,"profit":false}]

Erasca Inc Ratios

Erasca Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ERAS
Cash Ratio 9.68
Current Ratio 10.04

Erasca Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ERAS
ROA (LTM) -18.28%
ROE (LTM) -33.27%

Erasca Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ERAS
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Erasca Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ERAS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 13.95
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Erasca Inc share price today?

Erasca Inc (ERAS) share price today is $14.97

Can Indians buy Erasca Inc shares?

Yes, Indians can buy shares of Erasca Inc (ERAS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ERAS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Erasca Inc be purchased?

Yes, you can purchase fractional shares of Erasca Inc (ERAS) via the Vested app. You can start investing in Erasca Inc (ERAS) with a minimum investment of $1.

How to invest in Erasca Inc shares from India?

You can invest in shares of Erasca Inc (ERAS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ERAS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Erasca Inc shares
What is Erasca Inc 52-week high and low stock price?

The 52-week high price of Erasca Inc (ERAS) is $16.41. The 52-week low price of Erasca Inc (ERAS) is $1.01.

What is Erasca Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Erasca Inc (ERAS) is

What is Erasca Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Erasca Inc (ERAS) is 13.95

What is Erasca Inc dividend yield?

The dividend yield of Erasca Inc (ERAS) is 0.00%

What is the Market Cap of Erasca Inc?

The market capitalization of Erasca Inc (ERAS) is $4.71B

What is Erasca Inc's stock symbol?

The stock symbol (or ticker) of Erasca Inc is ERAS

How Can Investors Use Erasca Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Erasca Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Erasca Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Erasca Inc shares for Indian investors?

When investing in Erasca Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Erasca Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Erasca Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Erasca Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Erasca Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top